Five notes:
1. The transaction will value 23andMe at about $3.5 billion.
2. 23andMe CEO and co-founder Anne Wojcicki and Sir Richard Branson, the billionaire founder of the Virgin Group, are each investing $25 million into the $250 million private investment in a public equity deal.
3. The merger will fund additional growth investments in 23andMe’s consumer health and therapeutics businesses. In December, the company raised nearly $85 million for its corporate initiatives.
4. 23andMe has developed more than 30 therapeutic programs, spanning oncology, respiratory, cardiovascular diseases and more.
5. The transaction is expected to close in the second quarter of this year.
More articles on consumerism:
Yale taps Gozio Health to develop mobile platform
Fertility app company accused of sharing private data to sell ads settles with FTC
Google finalizes $2.1B Fitbit acquisition: 5 details
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
